Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

  • STATUS
    Recruiting
  • End date
    Jun 14, 2024
  • participants needed
    44
  • sponsor
    Samsung Medical Center
Updated on 28 June 2022

Summary

Pemetrexed in combination with erlotinib as a salvage treatment in patients with metastatic biliary tract cancer (BTC) who failed gemcitabine containing chemotherapy

Description

Biliary tract carcinoma (BTC) is rare in the Europe and the United States, but not uncommon in Asia and Latin America. The tumor arises from the ductular epithelium of the biliary tree within the liver (intrahepatic), the extrahepatic ducts (extrahepatic), or the gallbladder. Intrahepatic cancer is steadily increasing in the Western world. BTCs carry a poor prognosis with 1-year survival rate of 25%. Although surgery remains the only curative treatment for BTC, most patients present with advanced disease and die within a few months of diagnosis. While a combination of gemcitabine and platinum agents seems to be a conclusive treatment option as first-line treatment until now, the role or the optimal regimen for second-line treatment has not been established.

Pemetrexed, a multitarget antifolate which inhibits thymidylate synthase, dihydrofolate reductase and glycinamide ribonucleotide formyltransferase, was approved for the treatment of lung cancer and mesothelioma. In addition to its therapeutic efficacy, pemetrexed has tolerable safety profile and is considered as important therapeutic option for patients of poor performance statue or older age. Pemetrexed was studied in combination with gemcitabine in BTC patients and needs further research in BTC patients. Erlotinib is EGFR tyrosine kinase inhibitor. In BTC and pancreatic cancer, erlotinib showed prolonged survival in combination with chemotherapy. Moreover, the addition of erlotinib to gemcitabine and oxaliplatin showed antitumour activity in our previous phase III trial. And combination of pemetrexed and erlotinib showed tolerable safety profile in lung cancer trial.

So we plan this study to evaluate the efficacy and safety of pemetrexed in combination with erlotinib as a second line treatment in biliary tract cancer

Details
Condition Biliary Tract Cancer
Treatment Erlotinib, Pemetrexed 500 MG
Clinical Study IdentifierNCT03110484
SponsorSamsung Medical Center
Last Modified on28 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Provision of a signed written informed consent Age ≥ 20 Histologically or cytologically
confirmed carcinoma of biliary tract (intrahepatic, extrahepatic cholangiocarcinoma and
gall bladder cancer) Unresectable or metastatic Progression after treatment with first line
gemcitabine-based chemotherapy ECOG performance status of 0~2 Measurable lesion per RECIST
1 criteria Expected life expectancy ≥ 3months Adequate marrow, hepatic, renal and cardiac
functions

Exclusion Criteria

Poor performance statue Other primary cancer except properly treated non-melanoma skin
cancer, cured cervix carcinoma in situ and other cured solid tumor without evidence of
recurrence after 5 years of curative treatment
Severe co-morbid illness and/or active infections Any other clinical trial therapeutics
within 14 days Any anti-cancer therapy within 3 weeks prior to initiation of study
treatment (radiotherapy, systemic chemotherapy) CTCAE grade 2 or more adverse events
remained except alopecia QTcB > 480msec or family history of QT prolongation Current heart
problem such as: pooly controlled hypertension
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note